Key Highlights
- Third quarter loss per share was USD 0.52 against an estimated USD 0.34 loss, with no Revenue reported.
- Net loss was USD 34.4 million for the quarter and USD 70.5 million for the nine months.
- Cash, equivalents and marketable securities were USD 108.5 million, and the accumulated Deficit was USD 517.0 million.
- The company plans an NDA for rezatapopt in platinum-resistant ovarian cancer in the first quarter of 2027.
PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, reported a third quarter 2026 loss of USD 0.52 per share, wider than the USD 0.34 estimated loss. The company reported no revenue. Net loss was USD 34.4 million for the quarter and USD 70.5 million for the nine months, and the accumulated deficit was USD 517.0 million.
The quarter included expenses linked to the August 2026 public offering, including offering costs allocated to liability-classified common stock warrants that were expensed on issuance. There were no comparable amounts in the third quarter of 2025.
Spending and Cash
For the nine months, Research and Development expenses decreased USD 8.7 million, largely from lower contract research organization costs for the lead candidate, rezatapopt. General and administrative expenses were USD 11.9 million, against USD 12.9 million. Cash, cash equivalents and marketable securities were USD 108.5 million at September 30. No shares were sold under the at-the-market program in the quarter or nine months.
The filing refers to substantial doubt about Going Concern disclosed in the second quarter report. It states that cash, equivalents and marketable securities are sufficient to fund planned operations for at least one year from the date of the quarterly report.
Rezatapopt and the PYNNACLE Trial
The company began the Phase 1/2 PYNNACLE trial of rezatapopt in October 2020 and was granted FDA Fast Track Designation for solid tumors with a p53 Y220C mutation. After an End of Phase 1 meeting with the FDA in July 2023 reached alignment on the Phase 2 dose and design, the company dosed its first patient in the pivotal Phase 2 monotherapy portion in the first quarter of 2024.
Interim Phase 2 data were announced in September 2025 and updated in October 2025, and interim ovarian cancer data were presented in April 2026. In March 2026 the FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian, fallopian tube and primary peritoneal cancer. Enrollment of platinum-resistant or refractory ovarian cancer patients for the primary analysis is complete.
The company strategy is to seek approval under an accelerated pathway and it believes the Phase 2 portion of PYNNACLE has the potential to serve as a pivotal study. It plans to submit its initial New Drug Application for Accelerated Approval in platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
The filing's legal proceedings item states management is not currently involved in any litigation it considers capable of having a material adverse effect.
Items to Follow
The NDA timing, further PYNNACLE data, the effect of Warrant Fair Value changes on reported loss and cash relative to spending are the items to follow.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...